CJC-1295 with DAC 5 mg

Research Peptide for Growth Hormone Regulation · Recovery · Metabolic Studies

CJC-1295 with DAC 5 mg is a long-acting research peptide designed to study the effects of continuous growth hormone (GH) release. A synthetic analog of growth hormone–releasing hormone (GHRH), CJC-1295 with DAC binds to pituitary receptors to promote natural GH and IGF-1 production. The DAC (Drug Affinity Complex) extension allows the peptide to remain active for days, offering a model for sustained GH elevation and long-term endocrine modulation.

Formulated for research use only, CJC-1295 with DAC 5 mg provides consistent purity and potency for controlled endocrine and regenerative studies.

Scientific Overview

CJC-1295 is a modified GHRH analog that differs from its shorter-acting counterpart, CJC-1295 No DAC, through its DAC attachment. The DAC binds to plasma proteins, significantly extending half-life and systemic activity.
This long-duration action makes CJC-1295 with DAC 5 mg ideal for examining the effects of sustained GH secretion, anabolic signaling, and metabolism regulation.
In preclinical studies, prolonged GH stimulation has been associated with improved tissue repair, enhanced recovery, and increased lean body mass.

Key Research Applications

Researchers utilize CJC-1295 with DAC 5 mg to explore:

• Endocrine Modulation – Investigating GH and IGF-1 secretion dynamics under long-acting conditions.
• Muscle Growth and Recovery – Assessing tissue-regeneration effects of prolonged GH activity.
• Metabolic Adaptation – Studying lipid metabolism, glucose control, and nutrient partitioning.
• Anti-Aging and Longevity Models – Examining cellular repair and protein-synthesis regulation.
• Combination Research – Evaluating synergy with short-acting GHRPs such as Ipamorelin 5 mg for dual-pathway stimulation.

Because of its extended bioactivity, CJC-1295 with DAC 5 mg enables researchers to compare acute versus sustained GH-release patterns.

Mechanism of Action

CJC-1295 with DAC 5 mg interacts with GHRH receptors in the anterior pituitary to stimulate growth hormone release.
The DAC component binds to serum albumin, protecting the peptide from rapid enzymatic breakdown and prolonging its presence in circulation.
Research indicates CJC-1295 with DAC 5 mg may:

• Increase plasma GH and IGF-1 concentrations.
• Support cellular recovery and protein synthesis.
• Enhance energy utilization and lean-tissue development.
• Improve tissue healing and sleep quality through consistent GH rhythm.

These mechanisms make it a valuable model compound for studying long-term GH regulation and metabolic homeostasis.

Formulation and Supply

GRAM Peptides provides CJC-1295 with DAC 5 mg as a lyophilized peptide for sterile reconstitution.
Each vial contains 5 mg of pure compound verified by third-party laboratory testing. The peptide is stable when stored under recommended refrigerated conditions (2–8 °C).

Researchers can compare outcomes using both CJC-1295 with DAC 5 mg and CJC-1295 No DAC 5 mg to differentiate the duration and pattern of GH release.

Why Researchers Choose GRAM Peptides

• Pharmacist-Formulated – Created by a licensed compounding pharmacist with over two decades of peptide experience.
• Made in the USA – Manufactured under ISO-compliant clean-room standards.
• Third-Party Tested – Independent laboratories verify purity, potency, and peptide identity.
• Transparent Labeling – Each vial includes full COA, lot number, and expiration data.

GRAM Peptides ensures reproducibility and consistency for high-integrity research applications.

Common Research Areas

• Endocrine modulation and GH axis studies
• Tissue regeneration and wound-healing models
• Metabolic and energy-balance regulation
• Cellular longevity and recovery pathways

For additional data, researchers may reference publications through the National Library of Medicine (PubMed) discussing GHRH analog pharmacodynamics and growth hormone modulation.

Frequently Asked Questions

What is CJC-1295 with DAC 5 mg used for in research?
It’s examined for its effects on growth hormone release, tissue regeneration, and metabolic regulation.

How does CJC-1295 with DAC differ from the No DAC form?
The DAC-bound form has a longer half-life, promoting sustained GH and IGF-1 levels, whereas the No DAC form supports short-term GH pulsatility studies.

Is CJC-1295 with DAC FDA-approved?
No. CJC-1295 with DAC 5 mg is for Research Use Only (RUO) and is not approved for human or veterinary medical use.

How is it supplied?
Each vial contains 5 mg of lyophilized peptide intended for sterile reconstitution under laboratory conditions.

Related Peptides for GH Studies

• CJC-1295 No DAC 5 mg – Short-acting GHRH analog for pulsatile GH release.
• Ipamorelin 5 mg – GHRP analog often paired with CJC-1295 for combination research.
• Tesamorelin 10 mg – Investigated for IGF-1 stimulation and fat metabolism regulation.

Explore the complete Growth Hormone Support Collection from GRAM Peptides.

Disclaimer

CJC-1295 with DAC 5 mg is sold for Research Use Only (RUO). Not for human consumption, medical, or diagnostic use